Please enable javascript for best website experience

Infections Associated with the Use of Novel Cancer Therapies

This online enduring material will provide vital information on infections associated with the use of novel cancer therapies.

Overview
Learning Module
Course Credit

Course Description
Recently, a number of regulatory and technological factors have led to the much-needed introduction of new anti-infectives for bacterial, viral and fungal infections. These advances have posed significant issues in learning for the practitioner to understand the appropriate use of these agents as well as their limitations and potential toxicities. Similarly, the rapid expansion of biological agents and other compounds in oncology have led to significant risk for infections, so that the practicing infectious diseases practitioner and oncologist should know the risks, presentations and treatments for these infections. This online enduring material will provide vital information on infections associated with the use of novel cancer therapies.

Who Should Attend?
Physicians, Nurses(RNs/LVNs), Nurse Practitioners, Physician Assistants, Pharmacists, First Responders, EMT, Paramedics, Medical Assistants and all other healthcare professionals who come into contact with patients and the general public.

Learning Objectives

  • Describe the infectious diseases associated with the use of novel cancer therapies recently introduced into clinical practice
  • Describe the overlap in clinical presentation of syndromes associated with the use of novel agents and the common infectious diseases seen in this patient population
  • Describe the application of measures that can prevent opportunistic infections in patients receiving therapy with novel agents

Method of Participation
This activity is in HTML format.

To receive a maximum of 0.50 AMA PRA Category 1 Credits™ you should:

  • View the materials in this enduring material
  • Complete and submit the CME registration and evaluation forms

The estimated time to complete this activity, including review of the materials, is 0.75 hours.

Hardware/software requirements: Activities should be viewed with recent versions of common browsers, including Internet Explorer, Firefox, and Google Chrome.

Criteria for Successful Completion
Learner must successfully complete the learning module, in order to obtain continuing education credit and/or a certificate of attendance.

CME Accreditation Statement and Designation Statement
The UT Health San Antonio Joe R. & Teresa Lozano Long School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Joe R. & Teresa Lozano Long School of Medicine has designated this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Academy of Physician Assistants (AAPA), American Academy of Nurse Practitioners (AANP) and the American Nurses Credentialing Center (ANCC) accepts certificates of attendance for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Healthcare professionals receiving a certificate of attendance should consult with their licensing board for information on applicability and acceptance.

Terms of Approval
March 2019 through March 2022. Original Release date – March 2019

Disclosures
It is the policy of the Long School of Medicine to insure balance, independence, objectivity, and scientific rigor in all its educational programs and to ensure that such activities are independent of the control of commercial interests. All faculty participating in any Long School of Medicine directly or jointly provided programs are expected to disclose all relevant financial relationships with any commercial interest to the Long School of Medicine, CME Office. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

The Office of CME and Thomas F. Patterson, MD, content reviewer, have reviewed all financial disclosure information for all speakers, facilitators, and planning committee members, have determined, and resolved all conflicts of interests.

The following individuals do not have a relevant financial relationship with commercial interests to disclose.

Leticia Z. Bresnahan, MBA, CHCP – PLANNER
Director, Office of Continuing Medical Education
Joe R. and Teresa Lozano Long School of Medicine
UT Health San Antonio
San Antonio, TX

Disclosure: Nothing to disclose

Kelly Echevarria, PharmD, BCPS, AQ-ID – SPEAKER
National Clinical Pharmacy Program Manager, Infectious Diseases
Veterans Healthcare Administration Pharmacy Benefits Management
Department of Veterans Affairs
San Antonio, TX

Disclosure: Nothing to disclose

Cindie Garza, BBA – PLANNER
Senior Conference Coordinator, Office of Continuing Medical Education
Joe R. and Teresa Lozano Long School of Medicine
UT Health San Antonio
San Antonio, TX

Disclosure: Nothing to disclose

Pablo Okhuysen, MD, FACP, FIDSA – SPEAKER
Professor of Infectious Diseases
Department of Infectious Diseases Infection Control & Employee Health
Director of the Onco-Transplant Infectious Disease Fellowship Program
McGovern Medical School
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure: Nothing to disclose

The following individuals have disclosed a relevant financial relationship with commercial interests to disclose.

Roy Chemaly, MD, MPH, FIDS, FACP – SPEAKER
Professor of Medicine
Director, Infection Control
Director, Clinical Virology Research Program
Department of Infectious Diseases Infection Control & Employee Health
McGovern Medical School
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure: receives fees for non-CME services received directly from commercial interests from Merck; contracted research from Merck, Chimerix, Ansun Pharmaceuticals, Xenex, Ablynx, Gilead, Oxford Immunotec, AiCuris, and Pulmotec; and has an ownership interest from Xenex.

Ruben A. Mesa, MD – PLANNER
Professor of Medicine
Joe R. and Teresa Lozano Long School of Medicine
UT Health San Antonio
Director
Mays Cancer Center at UT Health San Antonio MD Anderson
San Antonio, TX

Disclosure: consultant for Novartis and Sierra Oncology; contracted research for Incyte, Celgene, Genentech, and CTI.

Jan E. Patterson, MD, MS, FACP, FIDSA – PLANNER
Professor of Medicine, Division of Infectious Diseases, Department of Medicine
Associate Dean for Quality and Lifelong Learning
Joe R. and Teresa Lozano Long School of Medicine
UT Health San Antonio
San Antonio, TX

Disclosure: Her spouse, Thomas F. Patterson, MD, is a consultant for Amplyx, Astellas, Basilea, Gilead, Merck, Pfizer, Scynexis, and Toyama; and contracted research for Cidara.

Thomas F. Patterson, MD, FACP, FIDSA – PLANNER AND SPEAKER
Professor of Medicine, Division of Infectious Diseases, Department of Medicine
Vice Chair for Faculty Development
Joe R. and Teresa Lozano Long School of Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX

Disclosure: Consultant for Amplyx, Astellas, Basilea, Gilead, Merck, Pfizer, Scynexis, and Toyama; and contracted research for Cidara

Contact Information
Office of Continuing Medical Education
Email: cme@uthealthsa.org
Phone: 1(866) 601-4448 or (210)-567-4491

Learning Module
Course Credit